ABAna Beatriz Baston

Ana Beatriz Baston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Beatriz Baston has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 12 May 2026
      • Vol. 84  (4) , 1-7
    Open Access

    A single-site retrospective cohort on the profile of in-hospital stroke: an alarming sentinel of systemic failures.

    by Ana Beatriz Marangoni Baston, Pedro Machry Pozzobon, Italo Merino Loes, Gabriel Pinheiro Modolo, Daniel Fabiano Barbosa Dos Santos, Natália Cristina Ferreira, Silméia Garcia Zanati Bazan, Gustavo José Luvizutto, Rodrigo Bazan, Cristiane Mendes-Chiloff

    In-hospital stroke is associated with delayed recognition, reduced access to acute treatment, and worse outcomes, particularly in low- and middle-income countries. To characterize the clinical profile, care processes, and outcomes of patients with ischemic stroke occurring during hospitalization. The present retrospective cohort study included adult patients with ischemic stroke diagnosed during hospitalization at a comprehensive stroke center. Stroke recognition time was used as the reference point. Clinical characteristics, stroke severity, acute treatment, and in-hospital outcomes were analyzed. Primary outcomes were in-hospital mortality, discharge destination, and functional independence. Fifty-two patients were included. Most strokes occurred in patients admitted for non-neurological conditions, mainly in surgical specialties. Stroke recognition was delayed in a relevant proportion of cases, and reperfusion therapy was infrequently performed, with no procedure-related complications. Moderate-to-severe strokes were common. In-hospital mortality was 9.6%, and functional status significantly declined from admission to discharge. Most patients received therapeutic care planning and were referred for rehabilitation. In-hospital ischemic stroke predominantly affects patients hospitalized for non-neurological conditions and is frequently recognized late, limiting access to reperfusion therapies. These findings highlight important gaps in in-hospital stroke detection and support the implementation of structured rapid-response protocols.

  • Open Access

    Diagnostic challenges in sporadic hemiplegic migraine: a case report

    by Itamar Meireles Santos, Patrick Emanuell Sousa-Santos, Tarcísio Nunes Alvarenga, Pedro Machry Pozzobon, Ana Beatriz Baston, Igor de Lima e Teixeira

    Case Presentation Female, 62 years old, history previous of hypertension and multiple cavernomatosis, admitted to our service emergency room with hypothesis of stroke. The patient presented headache associated with nausea and phosphenes in the right eye, with evolution for right hemiplegia. However, she showed complete and spontaneous reversal of symptoms, in a few minutes. The patient presented similar symptoms with annual recurrence since 2019, always following migraine attack. She denied familiar history of migraine. Brain MRI showed multiple cavernomatosis, with no signs of old or recent ischemia. Brain and cervical CT angiography and laboratorial tests were normal. She was then diagnosed with sporadic hemiplegic migraine, with no family report of the disease. She received treatment with Amitriptyline 50 mg per day, without further recurrences. Discussion Hemiplegic migraine (HM) is a rare form of migraine with motor aura, which includes fully reversible motor weakness. The aura of HM is most probably caused by cortical spreading depression, a self-propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex. Patients who are the first member of their family to have hemiplegic migraine are classified as having sporadic hemiplegic migraine. Some cases of sporadic hemiplegic migraine are caused by one of the genetic variants that cause familial hemiplegic migraine. The treatment of HM is empirical and mainly relies on principles of management of the common types of migraine, except for triptans use, medication historically contraindicated because of vasoconstrictor properties. Final comments Hemiplegic migraine is an important differential diagnosis with stroke in patients with migraine. Correct recognition of this condition can be a crucial factor in the treatment and prognosis of the patient in the emergency room. Keywords: hemiplegic migraine, motor aura, stroke mimics.

  • Open Access

    Intracranial hypertension associated with treatment of acute promyelocytic leukemia with all-trans retinoic acid (ATRA): a case report

    by Tarcísio N Alvarenga, Patrick Emanuell Sousa-Santos, Pedro Machry Pozzobon, Itamar Meireles Santos, Ana Beatriz Baston, Igor de Lima e Teixeira

    Case presentation Female, 18 years-old, without relevant family history, referred to Neurology by Hematology for headache. 3 years ago, she was diagnosed with Acute Promyelocytic Leukemia (APL) currently on maintenance therapy with All-Trans Retinoic Acid (ATRA). The patient reports that in all previous cycles presented headache with the following characters: one-side temporal location, pulsating quality, moderate intensity, with nausea and vomiting, photophobia and phonophobia, uncertain duration, with simple analgesics response. In the current cycle, she relates continuous pain, severe intensity and unresponsive to medication. On examination, there were no focal neurological findings and on funduscopic examination there was no papilledema. MRI and laboratorial tests were normal. Cerebrospinal fluid (CSF) opening pressure was 35 cmH2O, no other alterations. 15 milliliters of CSF were removed, with a closing pressure of 25 cmH2O. A hypothesis of Intracranial Hypertension associated with use of ATRA was made. Afterwards, there was important improvement of the headache, with residual pain of mild intensity. Therefore, Acetazolamide was started at a dose of 250 milligrams every 12 hours with complete resolution of symptoms. Discussion Acute myeloid leukemia (AML) comprises a heterogeneous group of aggressive blood cell cancers that arise from clonal expansion of malignant hematopoietic precursor cells in the bone marrow. Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of AML. APL is classified as acute promyelocytic leukemia with PML-RARA. The cytogenetic hallmark of APL is a translocation involving RARA, the retinoic acid receptor alpha locus on chromosome 17. Without treatment, APL is the most malignant form of AML, with a median survival of less than one month. (To see the complete abstract, please, check out the PDF).